revacept
Peptideexperimental
Clinical trial activity
3 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2006 (NCT01042964)
Timeline
Indications
Mechanism of action
- Protein sprouty homolog 1INHIBITOR
SPRY1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- revacept
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03312855 | Phase 2 | Nov 20, 2017 | AdvanceCor GmbH, German Center for Cardiovascular Research e. V. (DZHK), Ludwig Maximilians University, Technical University of Munich |
| NCT01645306 | Phase 2 | Mar 1, 2013 | AdvanceCor GmbH, Technical University of Munich, University of London |
| NCT01042964 | Phase 1 | Mar 1, 2006 | ABX-CRO, AdvanceCor GmbH, Procorde GmbH |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AdvanceCor GmbH | For profit | 3 | 2 | 2 | 2006 |
| Technical University of Munich | Academic/Hospital | 2 | 1 | 1 | 2013 |
| ABX-CRO | For profit | 1 | 0 | 1 | 2006 |
| German Center for Cardiovascular Research e. V. (DZHK) | Government | 1 | 0 | 1 | 2017 |
| Ludwig Maximilians University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Procorde GmbH | For profit | 1 | 0 | 1 | 2006 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2013 |
7 organizations
Page 1 / 1